We describe a prospective study in which bone mineral density (BMD) was measured in total body and regions, proximal femur, lumbar spine, and forearm in 84 apparently normal postmenopausal women with normal spinal radiographs and in 47 women with 1-10 wedged or compressed vertebrae. There was a hist
β¦ LIBER β¦
Bone repair in osteoporotic bone: postmenopausal and cortisone-induced osteoporosis
β Scribed by B. Cortet
- Publisher
- Springer-Verlag
- Year
- 2011
- Tongue
- English
- Weight
- 191 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0937-941X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Regional bone mineral density interrelat
β
Prof. B.E. Christopher Nordin; Barry E. Chatterton; Christopher G. Schultz; Alla
π
Article
π
2009
π
American Society for Bone and Mineral Research
π
English
β 643 KB
Effect of alendronate on bone mineral de
β
La-or Chailurkit; Wallaya Jongjaroenprasert; Sasithorn Rungbunnapun; Boonsong On
π
Article
π
2003
π
Springer
π
English
β 189 KB
Bone Turnover and the Response to Alendr
β
S. Gonnelli; C. Cepollaro; C. Pondrelli; S. Martini; A. Montagnani; R. Monaco; C
π
Article
π
1999
π
Springer
π
English
β 299 KB
Different Gene Expression Patterns in th
β
Bernadett Balla; JΓ‘nos P. KΓ³sa; JΓ‘nos Kiss; Adrienn Borsy; JΓ‘nos Podani; IstvΓ‘n
π
Article
π
2007
π
Springer
π
English
β 379 KB
Effects of denosumab on bone turnover ma
β
Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban
π
Article
π
2011
π
American Society for Bone and Mineral Research
π
English
β 272 KB
π 1 views
## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumabβtreat
Comparison of Bone and Total Alkaline Ph
β
N. B. Watts; D. K. Jenkins; J. M. Visor; D. C. Casal; P. Geusens
π
Article
π
2001
π
Springer-Verlag
π
English
β 141 KB